(c) 2024 PillSync.com

quetiapine 200 mg

1 INDICATIONS AND USAGE Quetiapine Extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic, or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia Quetiapine Extended-release tablets are indicated for the treatment of Schizophrenia. The efficacy of quetiapine extended-release tablets in Schizophrenia was established in one 6-week and one maintenance trial in adults with Schizophrenia. Efficacy was supported by three 6-week trials in adults with Schizophrenia and one 6-week trial in adolescents with Schizophrenia (13 to 17 years) treated with SEROQUEL [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder Quetiapine Extended-release tablets are indicated for the acute treatment of manic or mixed episodes associated with Bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of quetiapine extended-release tablets in manic or mixed episodes of Bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with Bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with Bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 to 17 years) with manic episodes associated with Bipolar I disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. Quetiapine Extended-release tablets are indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of quetiapine extended-release tablets were established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies (14.2) ]. Quetiapine Extended-release tablets are indicated for the maintenance treatment of Bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with Bipolar I disorder treated with SEROQUEL. The effectiveness of monotherapy for the maintenance treatment of Bipolar I disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2) ]. 1.3 Adjunctive Treatment of Major depressive disorder (MDD) Quetiapine Extended-release tablets are indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of quetiapine extended-release tablets as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment [see Clinical Studies (14.3) ]. 1.4 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I disorder Pediatric Schizophrenia and Bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric Schizophrenia, symptom profiles can be variable, and for Bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric Schizophrenia and Bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric Schizophrenia and Bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

accord healthcare inc.


2 years ago ROUND YELLOW I2 quetiapine 200 mg

ROUND YELLOW I2

2 years ago ROUND YELLOW I2 quetiapine 200 mg

I2 ROUND YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING Quetiapine Extended-release tablets, USP 150 mg (NDC 16729-109) white colored, round shaped, biconvex film coated tablets, debossed with 'I1' on one side and plain on other is supplied in bottles of 60 tablets with child-resistant closure (NDC 16729-109-12) and 500 tablets (NDC 16729-109-16). Quetiapine Extended-release tablets, USP 200 mg (NDC 16729-095) yellow colored, round shaped, biconvex, film coated tablets, debossed with “I2” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 16729-095-12). Quetiapine Extended-release tablets, USP 300 mg (NDC 16729-096) light yellow colored, round shaped, biconvex, film coated tablets, debossed with “I3” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 16729-096-12). Quetiapine Extended-release tablets, USP 400 mg (NDC 16729-097) white colored, round shaped, biconvex, beveled edge, film coated tablets, debossed with “I4” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 16729-097-12). Store quetiapine extended-release tablets, USP at 20ºC to 25ºC (68 ºF to 77 ºF). [See USP Controlled Room Temperature].


More pills like ROUND I2

Related Pills

quetiapine 300 mg

accord healthcare inc.

quetiapine 200 mg

accord healthcare inc.

prednisone 5 mg

amneal pharmaceuticals ny llc

Ibuprofen 200 MG Oral Tablet

Publix Super Markets Inc

ibuprofen 200 mg

Walgreen Company

ibuprofen 200 mg

Walgreen Company

ibuprofen 200 mg

Walgreen Company

Ibuprofen 200 MG Oral Tablet

Major Pharmaceuticals

Ibuprofen 200 MG Oral Tablet

Major Pharmaceuticals

Ibuprofen 200 MG Oral Tablet

Kmart Corporation

Ibuprofen 200 MG Oral Tablet

Major Pharmaceuticals

Ibuprofen 200 MG Oral Tablet

Major Pharmaceuticals












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site